<DOC>
	<DOCNO>NCT02357069</DOCNO>
	<brief_summary>This randomize , double-blind , parallel group , multicenter clinical study evaluate efficacy , safety , pharmacokinetics immunogenicity LBEC0101 compare Enbrel subject active Rheumatoid Arthritis despite Methotrexate therapy .</brief_summary>
	<brief_title>A Study Comparing LBEC0101 Enbrel® Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Male Female patient 20 year 75 year age signing Informed Consent . Diagnosed RA accord revised 1987 ACR criterion least 6 month prior screen Patients inadequate response MTX administer least 12 week begin screen period stable dose . patient active tuberculosis latent tuberculosis base current clinical symptom , chest Xray test IFNγ release assay screen patient follow concomitant disease and/or history within 24 week first administration investigational product study ; Serious infectious disease , Opportunistic infection , Chronic recurrent infectious disease patient seropositive result hepatitis B hepatitis C HIV patient follow disease ; Sepsis , Demyelinating disorder , Lymphoproliferative disease , Infection prosthetic joint , Autoimmune diseases rheumatoid arthritis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>